---
title: Cooper Companies (COO) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/coo
ticker: COO
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Instruments & Supplies
---
# Cooper Companies (COO)

Cooper Companies (COO) closed at $57.94 on Oct 16, 2026, overvalued by 13% vs its model value of $51.32 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $57.94 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $51.32 |
| Price vs model | overvalued by 13% vs model |
| Range of that model | $28.80 – $150.52 |
| Market value | $11.0B |
| P/E (fiscal 2025) | 31.0 |
| Net margin (fiscal 2025) | 9.2% |
| Free cash flow (fiscal 2025) | $433.7M |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 0.82 |
| Cost of capital (WACC) | 7.75% |
| Business classification | Mature & Stable (Low/slowing growth (~7% recent), Moderate margins (9% net margin), Highly cyclical earnings) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Worst performing this year | #39 | −29.3% | https://sweetvaluelab.com/lists/worst-performing-this-year |
| Insider buying | #14 | $1.9M | https://sweetvaluelab.com/lists/insider-buying |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $51.32 | $28.80 | $150.52 |
| DCF · Perpetuity growth · 10y | cross check | $54.08 | $31.71 | $151.04 |
| DCF · EBITDA exit · 5y | cross check | $108.37 | $79.40 | $142.36 |
| DCF · EBITDA exit · 10y | cross check | $101.19 | $69.92 | $142.62 |
| P/E · peers | cross check | $74.24 | $65.51 | $104.22 |
| P/E · own history | cross check | $133.65 | $109.45 | $160.31 |
| PEG | sanity check | $113.56 | $113.56 | $113.56 |
| EV/EBITDA · peers | cross check | $96.77 | $96.20 | $118.50 |
| EV/Revenue · peers | cross check | $70.85 | $36.73 | $179.18 |
| Earnings power value | cross check | $23.42 | $17.68 | $31.92 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Insider activity (SEC Form 4)

Past 90 days: 5 open-market buys ($1.9M) and 0 open-market sales ($0); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Sep 16, 2026 | Kurzius Lawrence Erik | Director | Open-market buy | 10,000 | $549,320 |
| Sep 11, 2026 | Rosebrough Walter M Jr | Director | Open-market buy | 7,000 | $378,770 |
| Sep 14, 2026 | Rosebrough Walter M Jr | Director | Open-market buy | 3,000 | $162,870 |
| Sep 14, 2026 | Kurzius Lawrence Erik | Director | Open-market buy | 10,000 | $539,150 |
| Sep 11, 2026 | Keel Paul A | Director | Open-market buy | 4,701.015 | $250,000 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Sep 9, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/711404/000162828026061160/coo-20260731.htm |
| Sep 9, 2026 | 8-K | 2.02 Results of Operations (Earnings); 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/711404/000162828026061155/coo-20260909.htm |
| Jun 5, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/711404/000162828026041305/coo-20260430.htm |
| Jun 4, 2026 | 8-K | 2.02 Results of Operations (Earnings); 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/711404/000162828026040823/coo-20260604.htm |
| May 4, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers | https://www.sec.gov/Archives/edgar/data/711404/000162828026029853/coo-20260504.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Bill Nygren | 2026-06-30 | 766,520 | $55.0M |
| Bridgewater | 2026-06-30 | 51,168 | $3.7M |
| Torray | 2026-06-30 | 23,286 | $1.7M |

3 tracked managers in all.

## About

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This seg…

---

Source: https://sweetvaluelab.com/stocks/coo (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.